FINNENCE ▪ THE WIRE FILE
THE WIRE · № 78052
Company■ Unclear/unknown
New Phase 3 trial: Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease — Beijing VDJBio Co., LTD.
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Small Castleman disease trial; rare-disease niche with limited market size.
Anti-IL-6R antibody tested in Castleman disease
CATALYST TO WATCH
Trial enrollment and data
MAIN RISK
Very small patient population
FULL DISPATCH
Sponsor: Beijing VDJBio Co., LTD.; Status: Recruiting; Conditions: Anti IL-6R, Castleman's Disease, Multicentric; Interventions: Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection, Placebo; Enrollment: 45 (estimated); First posted: 2026-10-13; NCT: NCT07872423
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy — SystImmune Inc.2026-10-13 12:00 UTC
New Phase 3 trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy — SystImmune Inc.2026-10-13 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda2026-10-13 12:00 UTC
New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda2026-10-13 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight — Amgen2026-10-13 12:00 UTC
New Phase 3 trial: Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight — Amgen2026-10-13 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.